Vyome Holdings (HIND) Other financing activities (2015 - 2024)

Vyome Holdings (HIND) posted quarterly Other financing activities of -$1.0 for Q4 2024, down 100.01% quarter-over-quarter from $6943.0 in Q3 2024.

Vyome Holdings (HIND) Other financing activities (2015 - 2024) Analysis & Trends

Vyome Holdings' Other financing activities history runs 9 years deep, the most recent figure standing at -$1.0 for Q4 2024.

In Q4 2024, Other financing activities changed N/A year-over-year to -$1.0; the TTM figure through Dec 2025 stood at $5942.0 (down 33.55% YoY), while the FY2025 annual figure was $6009.0, down 80.58% from the prior year.
Other financing activities for Q4 2024 stood at -$1.0, down from $6943.0 in the prior quarter.
The five-year high for Other financing activities was $9.5 million in Q1 2021, with the low at -$9.3 million in Q2 2021.
The 4-year median for Other financing activities is $6943.0 (2024), against an average of $435771.3.
The sharpest annual moves came in 2021 and 2022: Other financing activities sank 15850.85% in 2021, then slumped 99.9% in 2022.
Vyome Holdings' Other financing activities stood at $620000.0 in 2020, then soared by 386.77% to $3.0 million in 2021, then sank by 100.03% to -$1000.0 in 2022, then surged by 99.9% to -$1.0 in 2024.
Business Quant data shows HIND's Other financing activities at -$1.0 in Q4 2024, $6943.0 in Q3 2024, and -$1000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Vyome Holdings	16.07 Mn	8.18 Mn	11,658.00

Download Data